Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resminostat (4SC-201) in Sorafenib-Refractory Hepatocellular Carcinoma (SHELTER)
NCT00943449Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Jul 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Resminostat in hepatocellular carcinoma (HCC), sponsored by 4SC AG. Started Jul 2009; status: completed.
02
Drugs
Resminostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00943449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943449.